中国循证医学杂志

中国循证医学杂志

美国 2018 版恶性胸腔积液管理指南的解读

查看全文

目前恶性胸腔积液管理仍是临床工作面临的巨大挑战。2018 年 11 月,美国胸科协会、胸外科医师学会与胸部放射学学会基于最新临床研究证据,针对恶性胸腔积液管理中的 7 个临床问题,作出了相应临床意见推荐。本文对此进行解读,以期为规范恶性胸腔积液管理和未来相关研究提供参考依据。

The management of malignant pleural effusion remains a clinical challenge. In November 2018, American Thoracic Society, Society of Thoracic Surgeons, and Society of Thoracic Radiology summarized the recent advances and provided 7 recommendations for clinical problems of the management of malignant pleural effusion. This paper interprets these recommendations to provide references for management and research on malignant pleural effusion.

关键词: 恶性胸腔积液; 管理; 美国胸科协会; 美国胸外科医师学会; 美国胸部放射学学会; 指南; 解读

Key words: Malignant pleural effusion; Manegement; American Thoracic Society; American Society of Thoracic Surgeons; American Society of Thoracic Ranliology; Guideline; Interpretation

引用本文: 申永春, 陈磊, 文富强. 美国 2018 版恶性胸腔积液管理指南的解读. 中国循证医学杂志, 2019, 19(3): 271-275. doi: 10.7507/1672-2531.201812081 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. 中国恶性胸腔积液诊断与治疗专家共识组. 恶性胸腔积液诊断与治疗专家共识. 中华内科杂志, 2014, 53(3): 252-256.
2. Psallidas I, Kalomenidis I, Porcel JM, et al. Malignant pleural effusion: from bench to bedside. Eur Respir Rev, 2016, 25(140): 189-198.
3. Asciak R, Rahman NM. Malignant pleural effusion: from diagnostics to therapeutics. Clin Chest Med, 2018, 39(1): 181-193.
4. Feller-Kopman DJ, Reddy CB, DeCamp MM, et al. Management of malignant pleural effusions. An official ATS/STS/STR clinical practice guideline. Am J Respir Crit Care Med, 2018, 198(7): 839-849.
5. Grogan DR, Irwin RS, Channick R, et al. Complications associated with thoracentesis. A prospective, randomized study comparing three different methods. Arch Intern Med, 1990, 150(4): 873-877.
6. Gordon CE, Feller-Kopman D, Balk EM, et al. Pneumothorax following thoracentesis: a systematic review and meta-analysis. Arch Intern Med, 2010, 170(4): 332-329.
7. Mercaldi CJ, Lanes SF. Ultrasound guidance decreases complications and improves the cost of care among patients undergoing thoracentesis and paracentesis. Chest, 2013, 143(2): 532-538.
8. Tremblay A, Robbins S, Berthiaume L, et al. Natural history of asymptomatic pleural effusions in lung cancer patients. J Bronchology, 2007, 14(2): 98-100.
9. Porcel JM, Gasol A, Bielsa S, et al. Clinical features and survival of lung cancer patients with pleural effusions. Respirology, 2015, 20(4): 654-659.
10. Huggins JT, Sahn SA, Heidecker J, et al. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT. Chest, 2007, 131(1): 206-213.
11. Roberts ME, Neville E, Berrisford RG, et al. Management of a malignant pleural effusion: British thoracic society pleural disease guideline 2010. Thorax, 2010, 65(Suppl 2): ii32-40.
12. Bhatnagar R, Corcoran JP, Maldonado, et al. Advanced medical interventions in pleural disease. Eur Respir Rev, 2016, 25: 199-213.
13. Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry. Curr Opin Pulm Med, 2007, 13: 312-318.
14. Lee HJ, Yarmus L, Kidd D, et al. Comparison of pleural pressure measuring instruments. Chest, 2014, 146(4): 1007-1012.
15. Lan RS, Lo SK, Chuang ML, et al. Elastance of the pleural space: a predictor for the outcome of pleurodesis in patients with malignant pleural effusion. Ann Intern Med, 1997, 126(10): 768-774.
16. Scarci M, Caruana E, Bertolaccini L, et al. Current practices in the management of malignant pleural effusions: a survey among members of the European Society of Thoracic Surgeons. Interact Cardiovasc Thorac Surg, 2017, 24(3): 414-417.
17. Dresler CM, Olak J, Herndon JE 2nd, et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest, 2005, 127(3): 909-15.
18. Boshuizen RC, Vd Noort V, Burgers JA, et al. A randomized controlled trial comparing indwelling pleural catheters with talc pleurodesis (NVALT-14). Lung Cancer, 2017, 108: 9-14.
19. Davies HE, Mishra EK, Kahan BC, et al. Effect of an indwelling pleural catheter vs chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: the TIME2 randomized controlled trial. JAMA, 2012, 307(22): 2383-2389.
20. Demmy TL, Gu L, Burkhalter JE, et al. Optimal management of malignant pleural effusions (results of CALGB 30102). J Natl Compr Canc Netw, 2012, 10(8): 975-982.
21. Thomas R, Fysh ETH, Smith NA, et al. Effect of an indwelling pleural catheter vs talc pleurodesis on hospitalization days in patients with malignant pleural effusion: The AMPLE Randomized Clinical Trial. JAMA, 2017, 318(19): 1903-1912.
22. Iyer NP, Reddy CB, Wahidi MM, et al. Indwelling pleural catheter versus pleurodesis for malignant pleural effusions: a systematic review and meta-Analysis. Ann Am Thorac Soc, 2019, 16(1): 124-131.
23. Bhatnagar R, Keenan EK, Morley AJ, et al. Outpatient talc administration by indwelling pleural catheter for malignant effusion. N Engl J Med, 2018, 378(14): 1313-1322.
24. Clive AO, Jones HE, Bhatnagar R, et al. Interventions for the management of malignant pleural effusions: a network meta-analysis. Cochrane Database Syst Rev, 2016, (5): CD010529.
25. Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg, 1996, 62(6): 1655-1658.
26. Mummadi S, Kumbam A, Hahn PY. Malignant pleural effusions and the role of talc poudrage and talc slurry: a systematic review and meta-analysis. F1000Res, 2014, 3: 254.
27. 施焕中. 理性与无奈的选择: 美国2018版恶性胸腔积液管理指南解读. 协和医学杂志, 2018, 9(6): 89-91.
28. Ohm C, Park D, Vogen M, et al. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions. Am Surg, 2003, 69(3): 198-202.
29. Thornton RH, Miller Z, Covey AM, et al. Tunneled pleural catheters for treatment of recurrent malignant pleural effusion following fai led pleurodesis. J Vasc Interv Radiol, 2010, 21(5): 696-700.
30. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer, 1999, 86(10): 1992-1999.
31. Fysh ETH, Waterer GW, Kendall PA, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest, 2012, 142(2): 394-400.
32. Fysh ETH, Tremblay A, Feller-Kopman D, et al. Clinical outcomes of indwelling pleural catheter-related pleural infections: an international multicenter study. Chest, 2013, 144(5): 1597-1602.
33. Mahmood K, Bower C. Treatment of infection associated with tunneled pleural catheters. J Bronchology Interv Pulmonol, 2010, 17(1): 69-72.
34. Nasreen N, Mohammed KA, Brown S, et al. Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J, 2007, 29(4): 761-769.